| Literature DB >> 22937121 |
Durga Reddi1, Georgios N Belibasakis.
Abstract
Periodontitis is an infectious inflammatory disease that destroys the tooth-supporting (periodontal) tissues. Porphyromonas gingivalis is an oral pathogen highly implicated in the pathogenesis of this disease. It can exert its effects to a number of cells, including osteogenic bone marrow stromal cells which are important for homeostastic capacity of the tissues. By employing gene microarray technology, this study aimed to describe the overall transcriptional events (>2-fold regulation) elicited by P. gingivalis secreted products in bone marrow stromal cells, and to dissect further the categories of genes involved in bone metabolism, inflammatory and immune responses. After 6 h of challenge with P. gingivalis, 271 genes were up-regulated whereas 209 genes were down-regulated, whereas after 24 h, these numbers were 259 and 109, respectively. The early (6 h) response was characterised by regulation of genes associated with inhibition of cell cycle, induction of apoptosis and loss of structural integrity, whereas the late (24 h) response was characterised by induction of chemokines, cytokines and their associated intracellular pathways (such as NF-κB), mediators of connective tissue and bone destruction, and suppression of regulators of osteogenic differentiation. The most strongly up-regulated genes were lipocalin 2 (LCN2) and serum amyloid A3 (SAA3), both encoding for proteins of the acute phase inflammatory response. Collectively, these transcriptional changes elicited by P. gingivalis denote that the fundamental cellular functions are hindered, and that the cells acquire a phenotype commensurate with propagated innate immune response and inflammatory-mediated tissue destruction. In conclusion, the global transcriptional profile of bone marrow stromal cells in response to P. gingivalis is marked by deregulated homeostatic functions, with implications in the pathogenesis of periodontitis.Entities:
Mesh:
Year: 2012 PMID: 22937121 PMCID: PMC3427182 DOI: 10.1371/journal.pone.0043899
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Top five regulated gene categories according to cellular function.
| Genes regulated after 6 h | ||||
| Cellular function | Up-regulated | Down-regulated | ||
| Cancer | 33% | 22% | ||
| Cellular Movement | 16% | 10% | ||
| Cellular growth and proliferation | 24% | 20% | ||
| Cell-to-cell signalling | 14% | 9% | ||
| Haematological system (development and function) | 17% | 6% | ||
|
| ||||
|
|
|
| ||
| Cancer | 36% | 33% | ||
| Immunological disease | 25% | 9% | ||
| Antigen presentation | 29% | 7% | ||
| Cell-mediated immune response | 28% | 10% | ||
| Humoral immune response | 26% | 7% | ||
The percentage of genes regulated within each category is provided.
Genes regulated by P. gingivalis and associated with the categories of Skeletal/Muscle disorders and inflammatory response.
| Gene category | Fold Change (6 h) | Fold Change (24 h) | Skeletal & Muscle Development & Function | Skeletal & Muscle Disorders | Inflammatory Response |
|
| |||||
| Caspase 4 (CASP4) | 2.8 | 4.3 | X | ||
| Tumor necrosis factor receptor superfamily member 6 (FAS) | 7.8 | 11.5 | X | X | |
|
| |||||
| Cyclin D1 |
| X | |||
| p16 | 2.0 | X | X | ||
| p21 | 5.3 | X | X | X | |
|
| |||||
| CCL17 | 8.0 | 3.1 | X | X | |
| CCL2 | 17.6 | 20.7 | X | X | X |
| CCL3 | 3.3 | 40.0 | X | X | X |
| CCL5 | 9.0 | 86.8 | X | X | |
| CCL7 | 2.8 | 3.7 | X | X | X |
| CCL9 | 7.2 | 8.3 | X | X | |
| CX3CL1 | 10.6 | 4.7 | X | ||
| CXCL1 | 23.1 | 29.2 | X | X | |
| CXCL10 | 7.1 | 5.9 | X | X | |
| CXCL15 | 6.8 | X | X | ||
| CXCL2 | 2.6 | 3.0 | X | X | |
| CXCL4 | 2.3 | X | |||
| CXCL5 | 112.0 | X | |||
| CXCL7 | 16.0 | X | |||
| CXCL9 | 10.5 | 35.0 | X | X | |
| Interleukin 1, alpha (IL-1α) | 6.5 | X | X | X | |
| Interleukin 15 (IL-15) | − | X | X | ||
| Interleukin 6 (IL-6) | 23.2 | X | X | X | |
| Macrophage colony stimulating factor 1 (M-CSF1) | 2.7 | X | X | X | |
| Macrophage colony stimulating factor 2 (M-CSF2) | 2.4 | X | X | X | |
| Receptor activator of nuclear factor-κB ligand (RANKL) | 1.9 | X | X | X | |
| Tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B) | 3.4 | X | X | ||
|
| |||||
| Matrix GLA protein (MGP) |
| X | |||
|
| |||||
| Bone morphogenic protein 4 (BMP4) |
| X | X | ||
| Hepacyte growth factor (HGF) | 2.3 | X | X | ||
| Vascular endothelial growth factor (VEGF) | 2.1 | 2.8 | X | X | X |
|
| |||||
| GTP cyclohydrolase 1 (GCH1) | 9.0 | X | |||
| Guanylate binding protein 2 (GBP2) | 4.4 | 16.3 | X | ||
|
| |||||
|
| |||||
| Cyclooxygenase-2 (COX-2) | 3.2 | 2.3 | X | X | X |
| Haptoglobin (Hp) | 2.6 | 7.5 | X | ||
| Hemopexin (Hpx) | 7.0 | X | |||
| Lipocalin 2 (Lcn2) | 33.6 | 354.8 | X | ||
| Lipolysaccharide binding protein (LBP) | 2.4 | X | |||
| Myeloid differentiation protein-2 (MD-2) | −2.3 | X | |||
| Prostaglandin E synthase (PTGES) | 3.2 | X | |||
| Serum amyloid A3 (SAA3) | 144.8 | 143.9 | X | X | |
| Superoxide dismutase 2 (SOD2) | 2.3 | 3.2 | X | X | X |
|
| |||||
| Cathelicidin antimicrobial peptide (CAMP) | 9.4 | X | |||
| Complement component 1s (C1s) | 2.6 | X | X | ||
| Complement component 3 (C3) | 14.3 | X | X | ||
| Complement component 4B (C4B) | 2.3 | X | X | ||
| Complement factor B (CFB) | 19.9 | X | X | ||
| DHX58 | 2.7 | X | |||
| Interferon gamma inducible protein 47 (IFI47) | 3.1 | 2.9 | X | ||
| Interferon induced transmembrane protein 3 (IFITM3) | 3.2 | X | |||
| Interferon, alpha-inducible protein 27 (IFI27) | 2.6 | X | |||
| Macrophage antigen CD68 | 2.0 | X | |||
| Major histocompatibility 2, M region locus 3 (H2–M3) | 2.0 | 2.0 | |||
| Major histocompatibility complex, class I, C (HLA-C) | 2.6 | X | X | ||
| Major histocompatibility complex, class I, E (HLA-E) | 2.8 | X | |||
| Major histocompatibility complex, class II, DM alpha (HLA-DMA) | 2.0 | X | X | ||
| Major histocompatibility complex, class II, DQ beta 2 (HLA-DQβ2) | 3.4 | X | X | ||
| Pentraxin 3, long (PTX3) | 11.9 | 32.0 | X | ||
| Retinoic acid-inducible gene 1 protein (RIG-1) | 2.2 | X | |||
| S100 calcium binding protein A8 (S100A8) | 3.4 | X | X | ||
| Spondin 2 (SPON2)* | 2.2 | 2.8 | |||
| Ubiquitin D (UBD)* | 2.2 | 3.2 | |||
|
| |||||
| A disintegrin and metalloproteinase domain 12 (ADAM12) |
| X | |||
| A disintegrin-like and metalloproteinase with thrombospondin (ADAMTS7) | 2.1 | X | |||
| Cathepsin L (CTSL) | 2.2 | X | X | ||
| Matrix metalloproteinase 12 (MMP12) | 2.9 | X | |||
| Matrix metalloproteinase 13 (MMP13) | 9.3 | 8.4 | X | X | |
| Matrix metalloproteinase 13 (MMP17) | 3.4 | X | X | ||
| Matrix metalloproteinase 14 (MMP14) | -2.2 | X | X | ||
| Matrix metalloproteinase 3 (MMP3) | 35.8 | X | X | ||
| Matrix metalloproteinase 9 (MMP9) | 3.0 | X | X | ||
| Proteasome subunit, beta type, 8 (PSMB8) | 2.1 | X | |||
| Secretory leukocyte peptidase inhibitor (SLPI) | 4.9 | 19.5 | X | ||
| Tissue inhibitor of metalloproteinase 1 (TIMP1) | 2.1 | X | |||
|
| |||||
| CD44 | 2.2 | X | X | X | |
| Cluster of differentiation 14 (CD14) | 2.1 | X | |||
| Interferon Receptor 2 (IFNAR2) | 2.7 | X | X | ||
| Interleukin 1 receptor antagonist (IL1RN) |
| X | X | X | |
| Interleukin 10 receptor, beta (IL10RB) | 2.0 | X | |||
| Interleukin 13 receptor, alpha 1 (IL-13RA1) | 4.1 | X | |||
| Interleukin 13 receptor, alpha 2 (IL-13RA2) | 11.0 | X | |||
| Osteoprotegerin (OPG) | −4.0 | X | X | ||
| Toll like receptor 2 (TLR-2) | 3.7 | 12.6 | X | X | X |
| Tumor necrosis factor receptor superfamily, member 9 (TNFRSF9) | 3.9 | X | X | ||
|
| |||||
| Caveolin 1 (CAV1) |
| X | X | ||
| Vimentin (VIM) |
| X | |||
|
| |||||
| B-cell lymphoma 3-encoded protein (BCL3) | 2.7 | X | |||
| Growth arrest and DNA-damage-inducible, beta (GADD45B) | 2.6 | X | |||
| Immediate early response 3 (IER3) | 4.9 | 5.5 | X | ||
| Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon (IκBKE) | 1.7 | X | |||
| Inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase gamma (IκBKG) | 1.7 | X | |||
| Interleukin-1 receptor-associated kinase 3 (IRAK3) | 2.3 | X | X | ||
| Janus kinase 2 (JAK2) | 6.9 | X | |||
| Myeloid differentiation primary response gene (88) (MYD88) | 1.7 | X | X | X | |
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor (NF-κBIA) | 4.6 | 5.7 | X | X | X |
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor (NF-κBIZ) | 11.2 | 9.6 | X | ||
| Receptor-interacting serine-threonine kinase 2 (RIPK2) | 2.4 | 2.9 | X | ||
| Suppressor of cytokine signalling 3 (SOCS3) | 2.3 | 4.5 | X | X | X |
| TNFAIP3 interacting protein 1 (TNIP1) | 2.7 | 5.9 | X | ||
| Tumor necrosis factor, alpha-induced protein 3 (TNFAIP3) | 2.4 | 4.8 | X | X | X |
| WNT1 inducible signalling pathway protein 2 (WISP2) |
| X | |||
| V-rel reticuloendotheliosis viral oncogene homolog B (REL-B) | 4.0 | X | |||
|
| |||||
| CCAAT/enhancer-binding protein beta (CEBPβ) | 3.4 | 4.2 | X | X | X |
| FBJ murine osteosarcoma viral oncogene homolog (c-Fos) | 1.7 | 1.4 | X | X | X |
| Hairy-related transcription factor 1 (HEY1) | 2.1 | X | |||
| Jun B proto-oncogene (JUNB) | 2.6 | 5.4 | X | X | |
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NF-κB1) | 2.6 | X | X | ||
| Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (NF-κB2) | 2.2 | X | |||
| Sex determining region Y box 9 (SOX-9) |
| X | X | X | |
| Signal transducer and activator of transcription 3 (STAT3) | 2.6 | 2.6 | X | X | X |
| V-rel reticuloendotheliosis viral oncogene homolog A (avian) (REL-A) | 1.5 | X | |||
The genes regulated more than 2-fold by P. gingivalis were categorized according to ascribed roles in a) skeletal and muscle development and function, b) skeletal and muscle disorders, and c) inflammatory responses (horizontal categories). Within each of these thee categories, genes were sub-categorized according to ascribed cellular function (vertical categories). The fold-changes in expression (compared to control) at 6 h and 24 h are provided. The minus values (also in bold letters) indicate down-regulation. When a –fold change value is missing in one of the two time-points, the regulation of gene expression at that time-point was less that 2-fold.
Validation of microarray data by qPCR analysis.
| Fold changes in expression of selected genes by microarray | |||||
| COX-2 | LCN2 | OPG | RANKL | SAA3 | |
| 6 h | 3.2 | 33.6 | −4.0 | 144.8 | |
| 24 h | 2.3 | 354.8 | 1.9 | 143.9 | |
|
| |||||
|
|
|
|
|
| |
| 6 h | 10.1 | 352.2 | −4.0* | 5.4 | 4817.0 |
| 24 h | 5.7 | 4097.0 | −1.2 | 15.3* | 95296.4 |
Five of regulated genes were representatively selected for validation of their expression levels by qPCR, in comparison to the microarray. These were namely COX-2, LCN2, OPG, RANKL and SAA3. The values represent fold-changes of gene expression levels in response to P. gingivalis, in relation to control, by microarray analysis (A), or by qPCR analysis (B). The minus values (also in bold letters) indicate down-regulation. When a fold-change value is missing in one of the two time-points, the regulation of gene expression at that time-point was less that 2-fold. *p<0.05,
p<0.01,
p<0.001.